A Carbone1, A Gloghini, E Vaccher, G Marchetti, G Gaidano, U Tirelli. 1. Department of Pathology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, via Venezian 1, Milano I-20133, Italy. antonino.carbone@istitutotumori.mi.it
Abstract
BACKGROUND: Kaposi sarcoma associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) associated lymphomas, which often develop in human immunodeficiency virus (HIV) infected patients with advanced AIDS, present predominantly as primary effusion lymphoma (PEL) or, less frequently, as "solid" extracavitary based lymphomas, associated with serous effusions. These last lymphomas, also called "solid PEL", have been reported before the development of an effusion lymphoma and after resolution of PEL. Interestingly, KSHV/HHV-8 associated lymphomas that present as solid or extracavitary based lesions in HIV seropositive patients without serous effusions have been reported recently. METHODS/ RESULTS: This paper provides evidence for the existence of a previously undescribed KSHV/HHV-8 associated lymphoma in HIV seronegative patients without serous effusions. These lymphomas exhibit a predilection for the lymph nodes and display anaplastic large cell morphology. These tumours were completely devoid of common cell type specific antigens, including epithelial and melanocytic cell markers. B and T cell associated antigens and other commonly used lymphoid markers were absent or weakly demonstrable in a fraction of the tumour cells. Conversely, immunohistochemical studies showed strong immunostaining with plasma cell reactive antibodies. CONCLUSIONS: Analysis of viral infection and immunohistological studies are of primary importance to define this lymph node based KSHV/HHV-8 associated lymphoma with anaplastic large cell morphology and plasmablastic immunophenotype occurring in HIV seronegative patients without serous effusions.
BACKGROUND:Kaposi sarcoma associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) associated lymphomas, which often develop in human immunodeficiency virus (HIV) infectedpatients with advanced AIDS, present predominantly as primary effusion lymphoma (PEL) or, less frequently, as "solid" extracavitary based lymphomas, associated with serous effusions. These last lymphomas, also called "solid PEL", have been reported before the development of an effusion lymphoma and after resolution of PEL. Interestingly, KSHV/HHV-8 associated lymphomas that present as solid or extracavitary based lesions in HIV seropositivepatients without serous effusions have been reported recently. METHODS/ RESULTS: This paper provides evidence for the existence of a previously undescribed KSHV/HHV-8 associated lymphoma in HIV seronegative patients without serous effusions. These lymphomas exhibit a predilection for the lymph nodes and display anaplastic large cell morphology. These tumours were completely devoid of common cell type specific antigens, including epithelial and melanocytic cell markers. B and T cell associated antigens and other commonly used lymphoid markers were absent or weakly demonstrable in a fraction of the tumour cells. Conversely, immunohistochemical studies showed strong immunostaining with plasma cell reactive antibodies. CONCLUSIONS: Analysis of viral infection and immunohistological studies are of primary importance to define this lymph node based KSHV/HHV-8 associated lymphoma with anaplastic large cell morphology and plasmablastic immunophenotype occurring in HIV seronegative patients without serous effusions.
Authors: H Katano; T Suda; Y Morishita; K Yamamoto; Y Hoshino; K Nakamura; N Tachikawa; T Sata; H Hamaguchi; A Iwamoto; S Mori Journal: Mod Pathol Date: 2000-01 Impact factor: 7.842
Authors: Eric A Engels; Stefania Pittaluga; Denise Whitby; Charles Rabkin; Yoshiyasu Aoki; Elaine S Jaffe; James J Goedert Journal: Mod Pathol Date: 2003-05 Impact factor: 7.842
Authors: P Morand; M Buisson; H Collandre; B Chanzy; O Genoulaz; M J Bourgeat; N Pinel; P Leclercq; D Leroux; V Marechal; L Fritsch; R Ruigrok; J M Seigneurin Journal: Leuk Lymphoma Date: 1999-10
Authors: A Carbone; A Gloghini; L M Larocca; D Capello; F Pierconti; V Canzonieri; U Tirelli; R Dalla-Favera; G Gaidano Journal: Blood Date: 2001-02-01 Impact factor: 22.113
Authors: A Carbone; A M Cilia; A Gloghini; V Canzonieri; C Pastore; M Todesco; M Cozzi; T Perin; R Volpe; A Pinto; G Gaidano Journal: Int J Cancer Date: 1997-11-14 Impact factor: 7.396
Authors: Eric Oksenhendler; Emmanuelle Boulanger; Lionel Galicier; Ming-Qing Du; Nicolas Dupin; Tim C Diss; Rifat Hamoudi; Marie-Thérèse Daniel; Félix Agbalika; Chris Boshoff; Jean-Pierre Clauvel; Peter G Isaacson; Véronique Meignin Journal: Blood Date: 2002-04-01 Impact factor: 22.113
Authors: Eduardo M Queiroga; Gabriela Gualco; Lucimara Chioato; William J Harrington; Iguaracyra Araujo; Lawrence M Weiss; Carlos E Bacchi Journal: Am J Clin Pathol Date: 2008-08 Impact factor: 2.493
Authors: Amy Chadburn; Jonathan Said; Dita Gratzinger; John K C Chan; Daphne de Jong; Elaine S Jaffe; Yasodha Natkunam; John R Goodlad Journal: Am J Clin Pathol Date: 2017-02-01 Impact factor: 2.493
Authors: Y Benavente; G Mbisa; N Labo; D Casabonne; N Becker; M Maynadie; L Foretova; P L Cocco; A Nieters; A Staines; P Bofetta; P Brennan; D Whitby; S de Sanjosé Journal: Br J Cancer Date: 2011-09-27 Impact factor: 7.640
Authors: Antonino Carbone; Chiara C Volpi; Dario Caccia; Ambra V Gualeni; Anna M Cilia; Italia Bongarzone; Annunziata Gloghini Journal: Am J Surg Pathol Date: 2013-09 Impact factor: 6.394